Literature DB >> 15687336

Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies.

Naoki Hattori1, Katsuji Ikekubo, Yasuhisa Nakaya, Kaori Kitagawa, Chiyoko Inagaki.   

Abstract

Although macroprolactinemia due to antiprolactin (anti-PRL) autoantibodies is not uncommon among hyperprolactinemic patients, the pathogenesis of such macroprolactinemia is still unknown. We examined IgG subclasses of anti-PRL autoantibodies by enzyme immunoassay, and PRL phosphorylation and isoforms by Western blotting, mass spectrometry, and two-dimensional electrophoresis in six patients with anti-PRL autoantibodies and in 29 controls. PRL-specific IgG subclasses in patients with anti-PRL autoantibodies were heterogeneous, but five of six patients showed IgG4 predominance, which is known to be produced by chronic antigen stimulation. Western blot and mass spectrometric analyses revealed that human pituitary PRL was phosphorylated at serine 194 and serine 163, whereas serine 163 in serum PRL was dephosphorylated. On two-dimensional electrophoresis, serum PRL mainly consisted of isoform with isoelectric point (pI) 6.58 in control hyperprolactinemic patients, whereas acidic isoforms (pIs 6.43 and 6.29) were also observed in patients with anti-PRL autoantibodies. Our data first demonstrate that human pituitary PRL is serine phosphorylated and partially dephosphorylated in serum, and suggest that the acidic isoforms may give rise to chronic antigen stimulation in patients with anti-PRL autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15687336     DOI: 10.1210/jc.2004-1600

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Global Prevalence of Macroprolactinemia among Patients with Hyperprolactinemia: A Systematic Review and Meta-Analysis.

Authors:  Noor Azlin Azraini Che Soh; Najib Majdi Yaacob; Julia Omar; Aniza Mohammed Jelani; Noorazliyana Shafii; Tuan Salwani Tuan Ismail; Wan Norlina Wan Azman; Anis Kausar Ghazali
Journal:  Int J Environ Res Public Health       Date:  2020-11-06       Impact factor: 3.390

2.  Macroprolactinemia in a patient with invasive macroprolactinoma: a case report and minireview.

Authors:  Atanaska Elenkova; Zdravka Abadzhieva; Nikolai Genov; Vladimir Vasilev; Georgi Kirilov; Sabina Zacharieva
Journal:  Case Rep Endocrinol       Date:  2013-01-15

Review 3.  Macroprolactinemia: diagnostic, clinical, and pathogenic significance.

Authors:  Akira Shimatsu; Naoki Hattori
Journal:  Clin Dev Immunol       Date:  2012-12-04

4.  Serum macroprolactin levels in pregnancy and association with thyroid autoimmunity.

Authors:  Metin Guclu; Soner Cander; Sinem Kiyici; Ebru Vatansever; Arif Bayram Hacihasanoğlu; Gurcan Kisakol
Journal:  BMC Endocr Disord       Date:  2015-06-20       Impact factor: 2.763

5.  Macroprolactin; a frequent cause of misdiagnosed hyperprolactinemia in clinical practice.

Authors:  Vaishya Richa; Gupta Rahul; Arora Sarika
Journal:  J Reprod Infertil       Date:  2010-10

Review 6.  Macroprolactinemia: new insights in hyperprolactinemia.

Authors:  Miro Kasum; Slavko Oreskovic; Ivana Zec; Davor Jezek; Vlatka Tomic; Vesna Gall; Goran Adzic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

Review 7.  Hormone Immunoassay Interference: A 2021 Update.

Authors:  Khaldoun Ghazal; Severine Brabant; Dominique Prie; Marie-Liesse Piketty
Journal:  Ann Lab Med       Date:  2022-01-01       Impact factor: 3.464

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.